These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Atashrazm F; Dzamko N Clin Pharmacol; 2016; 8():177-189. PubMed ID: 27799832 [TBL] [Abstract][Full Text] [Related]
44. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707 [TBL] [Abstract][Full Text] [Related]
45. Ganoderic Acid A targeting Ahmad F Aging Med (Milton); 2023 Sep; 6(3):272-280. PubMed ID: 37711263 [TBL] [Abstract][Full Text] [Related]
46. Network metrics, structural dynamics and density functional theory calculations identified a novel Ursodeoxycholic Acid derivative against therapeutic target Parkin for Parkinson's disease. Naha A; Banerjee S; Debroy R; Basu S; Ashok G; Priyamvada P; Kumar H; Preethi AR; Singh H; Anbarasu A; Ramaiah S Comput Struct Biotechnol J; 2022; 20():4271-4287. PubMed ID: 36051887 [TBL] [Abstract][Full Text] [Related]
47. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709 [TBL] [Abstract][Full Text] [Related]
48. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. Gancia E; De Groot M; Burton B; Clark DE Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230 [TBL] [Abstract][Full Text] [Related]
49. Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Bolz SN; Salentin S; Jennings G; Haupt VJ; Sterneckert J; Schroeder M Comput Struct Biotechnol J; 2021; 19():3674-3681. PubMed ID: 34285770 [TBL] [Abstract][Full Text] [Related]
50. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252 [TBL] [Abstract][Full Text] [Related]
51. From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2. Mancini A; Mazzocchetti P; Sciaccaluga M; Megaro A; Bellingacci L; Beccano-Kelly DA; Di Filippo M; Tozzi A; Calabresi P Front Cell Neurosci; 2020; 14():158. PubMed ID: 32848606 [TBL] [Abstract][Full Text] [Related]
52. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721 [TBL] [Abstract][Full Text] [Related]
53. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach. Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370 [TBL] [Abstract][Full Text] [Related]
54. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. Göring S; Taymans JM; Baekelandt V; Schmidt B Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901 [TBL] [Abstract][Full Text] [Related]
55. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers. Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819 [TBL] [Abstract][Full Text] [Related]
56. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710 [TBL] [Abstract][Full Text] [Related]